The Journal of Headache and Pain

, Volume 8, Issue 4, pp 236–241

Botulinum toxin type-A therapy in cluster headache: an open study

  • Petra Sostak
  • Phillip Krause
  • Stefanie Förderreuther
  • Veronika Reinisch
  • Andreas Straube
Original

Abstract

The objective of this open single-centre study was to evaluate the efficacy and tolerability of botulinum toxin type-A (BTX-A) as add-on in the prophylactic treatment of cluster headache (CH). Twelve male patients with episodic (n=3) or chronic (n=9) CH, unresponsive to common prophylactic medications, were treated with a cumulative dose of 50 International Units (IU) BTX-A according to a standardised injection scheme into the ipsilateral pericranial muscles. One patient with chronic CH experienced a total cessation of attacks and in 2 patients attack intensity and frequency improved. In another patient with chronic CH typical attacks were not influenced, but an ipsilateral continuous occipital headache significantly improved. Patients with episodic CH did not benefit from BTX-A treatment. Tolerability was excellent. These findings provide evidence that BTX-A may be beneficial as an add-on prophylactic therapy for a limited number of patients with chronic CH.

Keywords

Cluster headache Botulinum toxin-A Headache/drug therapy Treatment outcome 

References

  1. 1.
    Russel MB (2004) Epidemiology and genetics of cluster headache. Lancet Neurol 3:279–283CrossRefGoogle Scholar
  2. 2.
    Favier I, Haan J (2005) Chronic cluster headache: a review. J Headache Pain 6:3–9PubMedCrossRefGoogle Scholar
  3. 3.
    Rosales RL, Arimura K, Takenaga S, Osame M (1996) Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19:488–496PubMedCrossRefGoogle Scholar
  4. 4.
    Silberstein S, Mathew N, Saper J, Jenkins S (2000) Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 40:445–450PubMedCrossRefGoogle Scholar
  5. 5.
    Brin MF, Swope DM, o’Brian C et al (2000) Botox for migraine: doubleblind, placebo-controlled, region-specific evaluation. Cephalalgia 20:421–422CrossRefGoogle Scholar
  6. 6.
    Mathew NT, Frishberg BM, Gawel M et al (2005) Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 45:293–307PubMedCrossRefGoogle Scholar
  7. 7.
    Farinelli I, Coloprisco G, De Filippis S, Martelletti P (2006) Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. J Headache Pain 7:407–412PubMedCrossRefGoogle Scholar
  8. 8.
    Porta M, Camerlingo M (2005) Headache and botulinum toxin. J Headache Pain 6:325–327PubMedCrossRefGoogle Scholar
  9. 9.
    Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48–56PubMedCrossRefGoogle Scholar
  10. 10.
    Freund BJ, Schwartz M (2000) The use of Botulinum toxin-A in the treatment of refractory cluster headache: case reports. Cephalalgia 20:325–331CrossRefGoogle Scholar
  11. 11.
    Smuts JA, Barnard PWA (2000) Botulinum Toxin type A in the treatment of headache syndromes: a clinical report on 79 patients. Cephalalgia 20:332CrossRefGoogle Scholar
  12. 12.
    Robbins L (2001) Botulinum Toxin A (Botox) for cluster headache: 6 cases. Cephalalgia 21:499–500Google Scholar
  13. 13.
    The International Classification of Headache Disorders, 2nd edn. Headache Classification Subcommittee of the International Headache Society (2004) Cephalalgia 24:44–48Google Scholar
  14. 14.
    Solomon S, Lipton RB, Newman LC (1990) Nuchal features of cluster headache. Headache 30:347–349PubMedCrossRefGoogle Scholar
  15. 15.
    Verslegers WR, Pickut BA, De Deyn PP (2006) Paroxysmal neuralgic upper cervical pain attacks: The lower syndrome of cluster headache. Clin Neurol Neurosurg 108:737–743PubMedCrossRefGoogle Scholar
  16. 16.
    Hardebo JE (1994) How cluster headache is explained as an intracavernous inflammatory process lesioning sympathetic fibers. Headache 34:125–131PubMedCrossRefGoogle Scholar
  17. 17.
    Sprenger T, Valet M, Hammes M et al (2004) Hypothalamic activation in trigeminal autonomic cephalgia: functional imaging of an atypical case. Cephalalgia 24:753–757PubMedCrossRefGoogle Scholar
  18. 18.
    May A, Bahra A, Buchel C et al (1998) Hypothalamic activation in cluster headache attacks. Lancet 352:275–278PubMedCrossRefGoogle Scholar
  19. 19.
    May A, Ashburner J, Buchel C et al (1999) Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nat Med 5:836–838PubMedCrossRefGoogle Scholar
  20. 20.
    Franzini A, Ferroli P, Leone M, Broggi G (2003) Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches: first reported series. Neurosurgery 52:1095–1099; discussion 1099–1101PubMedCrossRefGoogle Scholar
  21. 21.
    Leone M, Franzini A, Broggi G, Bussone G (2003) Hypothalamic deep brain stimulation for intractable chronic cluster headache: a 3-year follow-up. Neurol Sci 24Suppl 2:S143–145PubMedGoogle Scholar
  22. 22.
    Schoenen J, Di Clemente L, Vandenheede M et al (2005) Hypothalamic stimulation in chronic cluster headache: a pilot study of efficacy and mode of action. Brain 128:940–947PubMedCrossRefGoogle Scholar
  23. 23.
    Malick A, Strassman RM, Burstein R (2000) Trigeminohypothalamic and reticulohypothalamic tract neurons in the upper cervical spinal cord and caudal medulla of the rat. J Neurophysiol 84:2078–2112PubMedGoogle Scholar
  24. 24.
    Aoki KR (2005) Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. NeuroToxicology 26:785–793PubMedCrossRefGoogle Scholar
  25. 25.
    Wiegand H, Erdmann G, Wellhoner HH (1976) 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 292:161–165PubMedCrossRefGoogle Scholar
  26. 26.
    Welch MJ, Purkiss JR, Foster KA (2000) Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38:245–258PubMedCrossRefGoogle Scholar
  27. 27.
    Durham PL, Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44:35–42; discussion 42–33PubMedCrossRefGoogle Scholar
  28. 28.
    Nilsson Remal AIM, Laudon Meyer E, Cordonnier C, Goadsby PJ (2003) Placebo response in cluster headache trials: a review. Cephalalgia 23:504–510CrossRefGoogle Scholar
  29. 29.
    Monstad I, Krabbe A, Micieli G et al (1995) Preemptive oral treatment with sumatriptan during a cluster period. Headache 35:607–613PubMedCrossRefGoogle Scholar
  30. 30.
    Steiner TJ, Hering R, Couturier EGM et al (1997). Double-blind placebo-controlled trial of lithium in episodic cluster headache. Cephalalgia 17:673–675PubMedCrossRefGoogle Scholar
  31. 31.
    Nilsson Remahl AI, Ansjon R, Lind F, Waldenlind E (2002) Hyperbaric oxygen treatment of active cluster headache: a double blind placebo-controlled cross-over study. Cephalalgia 22:730–739.PubMedCrossRefGoogle Scholar
  32. 32.
    Cittadini E, May A, Straube A et al (2006) Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. Arch Neurol 63:1537–1542PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2007

Authors and Affiliations

  • Petra Sostak
    • 1
  • Phillip Krause
    • 1
  • Stefanie Förderreuther
    • 1
  • Veronika Reinisch
    • 1
  • Andreas Straube
    • 1
  1. 1.Department of Neurology, Klinikum GroßhadernLudwig-Maximilians UniversityMunichGermany

Personalised recommendations